In patients with locally advanced or metastatic cSCC who are not suitable for curative surgery or radiotherapy, systemic therapy is the standard of care, with immune checkpoint inhibitors (ICI) targeting PD-1 representing the preferred option. The gene discussed is PDCD1; the disease is skin squamous cell carcinoma.